Q1 EPS Forecast for Benitec Biopharma Lowered by Analyst

Benitec Biopharma Limited (NASDAQ:BNTC) – HC Wainwright decreased their Q1 2027 earnings per share estimates for Benitec Biopharma in a report released on Monday, September 28th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.29) per share for the quarter, down from their prior estimate of ($0.28). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.34) EPS.

A number of other brokerages have also weighed in on BNTC. Royal Bank Of Canada upgraded shares of Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th. Wall Street Zen downgraded Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Wedbush lifted their target price on Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Citigroup restated a “market outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, September 15th. Finally, Guggenheim downgraded Benitec Biopharma from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $9.75 on Wednesday. The stock has a market capitalization of $340.11 million, a PE ratio of -9.95 and a beta of 0.27. Benitec Biopharma has a 52-week low of $9.26 and a 52-week high of $16.76. The company has a 50-day simple moving average of $12.08 and a two-hundred day simple moving average of $11.97.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26).

Institutional Trading of Benitec Biopharma

Several large investors have recently modified their holdings of BNTC. GAMMA Investing LLC increased its position in Benitec Biopharma by 18.7% during the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 1,256 shares during the last quarter. Bank of America Corp DE boosted its position in Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 5,251 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in Benitec Biopharma in the first quarter worth about $186,000. Bank of New York Mellon Corp grew its stake in shares of Benitec Biopharma by 37.6% during the 1st quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 11,877 shares during the period. Finally, Empery Asset Management LP bought a new stake in shares of Benitec Biopharma during the 4th quarter valued at about $747,000. Institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.